World Health Organization

Google Cloud Announces New Generative AI Advancements for Healthcare and Life Science Organizations

Retrieved on: 
Tuesday, March 12, 2024

ORLANDO, Fla., March 12, 2024 /PRNewswire/ -- Today at HIMSS24, Google Cloud announced several new solutions to help healthcare and life sciences organizations enable interoperability, build a better data foundation for their businesses, and deploy generative AI (gen AI) tools to improve patient outcomes.

Key Points: 
  • These search and question-answering capabilities now integrate with MedLM , Healthcare Data Engine (HDE) and Cloud Healthcare FHIR APIs , making it easier for healthcare and life science organizations to build the data analytics and AI solutions needed for next era health systems.
  • Configurable cloud APIs: Healthcare application developers can integrate the medically-tuned search directly into the clinician workflow tools using configurable cloud APIs.
  • "Not all generative AI is created equal, and in healthcare, the stakes are particularly high," said Aashima Gupta, global director for Healthcare Strategy & Solutions, Google Cloud.
  • For more information on these technology advancements for healthcare and life sciences, stop by the Google booth #2512 at HIMSS24 , and please contact your Google Cloud sales team to learn more.

World Vaccine Congress Draws Leaders from Government, Science and Industry

Retrieved on: 
Monday, March 11, 2024

WASHINGTON, March 11, 2024 /PRNewswire/ -- The world's top experts and policymakers, including government leaders, renown researchers and company executives driving vaccine development, will gather to discuss the latest progress in vaccines — from efforts to inoculate bees to a discussion of pathogens that could cause the next pandemic — at the World Vaccine Congress April 1-4.

Key Points: 
  • "We have assembled the world's foremost experts and policymakers in the field of vaccination for the 2024 World Vaccine Congress," said Dr. Gregory A. Poland, Director of Mayo Vaccine Research Group, Mayo Clinic and a member of the Science Advisory Board.
  • "This event represents an unparalleled opportunity for collaboration and innovation and promises to drive meaningful progress in global health.
  • It is a unique and massive forum for discovery and access to leaders across the field."
  • In-depth sessions also cover vaccine supply and logistics, veterinary vaccines, emerging diseases, and vaccine delivery.

Zomi Frankcom is a tragic victim in the stalemated Israel-Hamas war, but don’t expect Australia’s approach to change much

Retrieved on: 
Friday, April 5, 2024

Talleyrand was an archetypal exponent of realpolitik, and history provides numerous examples of the validity of his remark.

Key Points: 
  • Talleyrand was an archetypal exponent of realpolitik, and history provides numerous examples of the validity of his remark.
  • One is the prolonged US bombing of North Vietnam, Cambodia and Laos during the Vietnam war in the late 1960s and early 1970s.
  • Though the ministry is managed by Hamas, the World Health Organization describes its data collection as “credible and well developed”.
  • Israel claims 13,000 of those killed were Hamas fighters, though it has not said how it calculated that figure.

Claims of poor coordination refuted

  • The IDF and defence ministry claimed the strikes on the World Central Kitchen vehicles followed misidentification and poor coordination at night in complex war conditions because of suspicion an armed militant was travelling with them.
  • The Israeli newspaper Haaretz, citing defence sources, has refuted these claims.
  • The army’s killing of seven aid workers in the Gaza Strip on Monday night “stemmed from poor discipline among field commanders, not a lack of coordination between the army and aid organisations”.

How will this affect Australia’s position?

  • Albanese said he expressed Australia’s outrage at Frankcom’s death and said he wanted “full accountability”.
  • He added that he made clear Australia believes humanitarian assistance must reach people in Gaza unimpeded and in large quantities.
  • It also suggested Netanyahu has a closer eye on his political standing in Israel than the international reaction to the deaths.

Don’t expect much change

  • The reality is not much is likely to change in terms of Australia’s dealings with Israel.
  • Foreign Minister Penny Wong has already made clear no Australian military equipment has been sold to Israel since the start of the Gaza war.
  • Australia’s defence exports to Israel are in any case miniscule – A$13 million over the past five years.
  • Wong has said many times Israel has the right to defend itself but the way it does so matters.


Ian Parmeter does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.

There are new flu vaccines on offer for 2024. Should I get one? What do I need to know?

Retrieved on: 
Wednesday, April 3, 2024

Although most cases are relatively mild, flu can cause more severe illness in young children and older people.

Key Points: 
  • Although most cases are relatively mild, flu can cause more severe illness in young children and older people.
  • Influenza virtually disappeared from Australia during the first years of the COVID-19 pandemic when public health restrictions reduced contact between people.
  • Since 2022, it has returned to a seasonal pattern, although the flu season has started and peaked a few months earlier than before 2020.

What goes into a flu vaccine?

  • Influenza strains are constantly changing due to genetic mutation, with the pace of genetic change much higher than for SARS-CoV-2 (the virus that causes COVID).
  • Read more:
    Flu vaccine won't definitely stop you from getting the flu, but it's more important than you think

    All current influenza vaccines in Australia contain four different strains (known as quadrivalent vaccines).

What’s different about new flu vaccines?

  • These include egg-based vaccines (Vaxigrip Tetra, Fluarix Tetra, Afluria Quad, FluQuadri and Influvac Tetra), cell-based vaccines (Flucelvax Quad), adjuvanted vaccines (Fluad Quad) and high-dose vaccines (Fluzone High-Dose Quad).
  • Until recently, the process of manufacturing flu vaccines has remained similar.
  • In some flu vaccines, adjuvants (components that stimulate the immune system) are included with the influenza antigens.
  • For example, an adjuvant is used in the Fluad Quad vaccine, recommended for over 65s.
  • Studies suggest adjuvanted influenza vaccines are slightly better than standard egg-based vaccines without adjuvant in older people.
  • Read more:
    Should I get the flu shot if I'm pregnant?

What should I do this year?

  • Influenza vaccines are also recommended in pregnancy to protect both the mother and the baby for the first months of life.
  • Influenza vaccines are widely available, including at GP clinics and pharmacies, while many workplaces have occupational programs.


In older people, a number of vaccines are now recommended: COVID and influenza, as well as one-off courses of pneumococcal and shingles vaccines. In general, most vaccines can be given in the same visit, but talk to your doctor about which ones you need.

Are there side effects?

  • These are expected and reflect the immune system reacting appropriately to the vaccine, and are mostly mild and short-term.
  • People with egg allergies should discuss this with their doctor, but in general, studies suggest they can safely receive any (including egg-based) influenza vaccines.
  • Serious side effects from the influenza vaccine, such as Guillain-Barré syndrome, a neurological complication, are very rare (one case per million people vaccinated).


Allen Cheng receives funding from the National Health and Medical Research Council and the Australian Department of Health and Aged Care. He is a member of the Australian Technical Advisory Group on Immunisation.

Consumer participation in the credit market during the COVID-19 pandemic and beyond

Retrieved on: 
Tuesday, April 2, 2024
Tax, BLS, Face, La Cava, Liquidity, Journal of Economic Perspectives, Special, MRO, Recovery, Next Generation, Child, Interview, Transport, Attanasio, Consumer behaviour, DFR, Research Papers in Economics, Post-Keynesian economics, Gross domestic product, .177 caliber, Great Moderation, European Commission, Vaccine, Employment, Loan, PDF, Hall, House, ECB, Unemployment, Risk, Shock, Education, Rutgers University Press, Quarterly Journal, Policy, Real estate economics, EU Council, Woman, HHS, World Health Organization, Section 4, Clutch (eggs), MIT Press, Omicron, De Nederlandsche Bank, Social science, Federal Reserve Bank, Modigliani, EDS, JEL, Christian Social Union (UK), Female, Section 3, COVID-19, The Journal of Finance, Journal, Classification, News, Journal of Monetary Economics, Oxford Economic Papers, Death, Insurance, Journal of Economics, FRB, FED, Credit, HFCS, Economy, Deficit reduction, Vaccination, Princeton University Press, Literature, CES, Application, University of Oxford, Paper, R.E, Quarterly Journal of Economics, Section 2, European Central Bank, Civil service commission, C23, COVID, Conference, European Council, Central bank, Lifting, HH, Political economy, Consumer confidence index, European Parliament, MIT, RRF, Monetary economics, Household, Perception, Section 5, Bank, Structure, Reproduction, Website, HICP, Aimé Dossche, Working paper, Housing, Cambridge, Massachusetts, Heart, Fabbri, American Economic Review, Partner, Data, Collection, Probability, Government, Real estate

We find that credit demand is highest when

Key Points: 
    • We find that credit demand is highest when
      the first lockdown ends and it drops when supportive monetary compensation schemes are implemented.
    • Credit is more likely to be
      accepted under favourable borrowing conditions and after the approval of national recovery plans.
    • We also find
      that demographic, economic factors, perceptions and expectations are associated with the demand for credit and
      the credit grant.
    • First, it adds to a rapidly growing literature on household
      borrowing behaviour during the COVID-19 pandemic; see, for example, Ho et al.
    • We provide evidence that credit applications and credit acceptances display a different pattern over
      time.
    • Credit is more likely to be accepted under favourable borrowing conditions and after the
      approval of national recovery plans.
    • In almost all countries
      households are significantly less likely to apply and to get their credit approved than in Germany.
    • In line with literature, we show that
      demographic and economic factors affect the probability for credit applications and credit approval.
    • In addition,
      the paper shows that consumer perceptions and expectations matter when they decide to apply for credit.
    • Introduction

      The participation of households in the credit market receives wide attention in the consumer finance literature
      because consumer credit enters the monetary policy transmission mechanism through the so-called ?credit
      channel?: changes in credit demand and supply have an effect on consumers' spending and investment, which in
      turn affect economic growth.

    • We use microdata from the ECB?s Consumer Expectations Survey (hereinafter CES), a survey that
      measures consumer expectations and behaviour in the euro area.
    • Its panel dimension allows for an assessment of
      how consumer behaviour changes over time and how consumers respond to critical economic shocks.
    • This way we can gauge how credit applications and credit acceptances change under different, almost
      opposite, borrowing conditions.
    • We also distinguish between the demand for long-term secured loans (mortgages) and for short-term
      uncollateralized loans (consumer loans).
    • ECB Working Paper Series No 2922

      3

      We use probit models to estimate the probability of the consumer to apply for credit and the credit being granted.

    • The rate peaks in 2020Q3 which reflects the rebound in the demand for loans when the first lockdown ended.
    • In almost all countries households are significantly less likely
      to apply and to get their credit approved than in Germany.
    • However,
      when it comes to credit acceptance, we observe that the two groups of households are more similar.
    • Finally, we find some heterogeneity with respect to the type of credit, particularly between secured and unsecured
      debt.
    • The demand for
      consumer credit is insignificant for liquid households and decreases significantly for constrained households in
      the last two quarters of our timespan.
    • The first consists of a recently growing literature which
      explores consumer behaviour in the credit market during the COVID-19 pandemic, mostly in the United States.
    • Sandler and Ricks (2020) show that consumers did not use credit card debt for financial liquidity in the early stage
      of the COVID-19 pandemic.
    • (2020) report that credit card applications and new mortgage loans
      declined during the first months of the pandemic in regions with more unemployment insurance claims.
    • Lu and
      Van der Klaauw (2021) show that there was a sharp drop in consumer credit demand, especially for credit cards.
    • (2022) document that there was a substantial decrease in the usage of credit cards and home equity lines
      of credit by Canadian consumers.
    • Our paper is also consonant with studies on the association between financial and demographic factors and
      consumers? participation in the credit market as well as on the demand for specific types of credit.
    • January 2020 ? October 2020 - The two main events are the outbreak of the COVID-19 pandemic and the
      consequential lockdowns in the euro area.
    • 4 If the
      respondent has applied for more than one type of credit, she is asked to refer to the most recent credit application.
    • Between 2021Q3 and 2022Q3 the acceptance
      rate stays above the average values, mirroring the easing of credit standards for consumer credit and other lending
      to households during this period.
    • Second, we can investigate the presence of nonlinearities in how liquidity and the credit type interact in explaining credit applications.
    • (2023) ? who show that in the United States the local pandemic severity had a strong
      negative effect on credit card spending early in the pandemic, which diminished over time.
    • First, we select mortgages and consumer credit as the two mostly reported categories for secured and

      13

      The full estimation results are reported in Table 3.

    • The right-hand side panel of Figure 6 shows that the demand for consumer credit is insignificant for both liquid
      and illiquid households.
    • It also shows that
      subjective perceptions of credit access, financial concerns and expectations on interest rates matter for the demand
      for credit.
    • In Bertola, G., Disney
      R., and Grant, C. (eds) The Economics of Consumer Credit, Cambridge MA, MIT Press.
    • Horvath, A., Kay, B. and Wix, C. (2023) The COVID-19 shock and consumer credit: Evidence from credit card
      data.
    • Magri, S. (2007) Italian households? debt: The participation to the debt market and the size of the loan.

Sharps Technology and Roncadelle Operations Sign Worldwide Sales and Distribution Agreement for their Innovative Portfolio of Safe Technology Drug Delivery Systems

Retrieved on: 
Thursday, March 7, 2024

The agreement, signed on March 4, 2024, lays the groundwork for further collaboration between Sharps and Roncadelle to develop and manufacture next-generation drug delivery products.

Key Points: 
  • The agreement, signed on March 4, 2024, lays the groundwork for further collaboration between Sharps and Roncadelle to develop and manufacture next-generation drug delivery products.
  • “We believe that this is just the beginning of Sharps’ collaboration with Roncadelle.
  • “This alliance underscores our unwavering commitment to innovation and excellence, reshaping standards within the global healthcare landscape.”
    Sharps Technology specializes in the development and manufacturing of innovative drug delivery systems.
  • As part of the cooperative agreement, Sharps and Roncadelle intend to collaborate on the development of new drug delivery products.

Jhpiego pledges support to countries working to eliminate cervical cancer

Retrieved on: 
Wednesday, March 6, 2024

Baltimore, Md., March 06, 2024 (GLOBE NEWSWIRE) -- On the eve of International Women’s Day, Jhpiego joined a historic wave of commitments to ending cervical cancer as a public health problem as part of the global Cervical Cancer Elimination Initiative meeting in Cartagena de Indias, Colombia .

Key Points: 
  • Baltimore, Md., March 06, 2024 (GLOBE NEWSWIRE) -- On the eve of International Women’s Day, Jhpiego joined a historic wave of commitments to ending cervical cancer as a public health problem as part of the global Cervical Cancer Elimination Initiative meeting in Cartagena de Indias, Colombia .
  • Jhpiego is also committed in supporting at least five other countries for HPV vaccine coverage improvement and/or implementation of tailored interventions to increase HPV vaccine coverage.
  • Jhpiego has long been committed to integrated programs that link improved screening and treatment for cervical cancer as well as accelerating vaccine uptake.
  • We are inspired by these new commitments to work together across the whole spectrum of cervical cancer responses; together we have the potential to save many more women’s lives.”

Psyence Biomedical’s Subsidiary, Psyence Australia, Receives Human Research Ethics Committee (HREC) Approval to Initiate Phase IIb Study

Retrieved on: 
Wednesday, March 6, 2024

NEW YORK, March 06, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd (NASDAQ:PBM) ("Psyence Biomed" or the "Company") is pleased to announce that its wholly-owned subsidiary, Psyence Australia (Pty) Ltd ("Psyence Australia"), has received full approval from the Australian Health Research Ethics Committee (HREC) to initiate its planned Phase IIb study in Melbourne, Australia.

Key Points: 
  • NEW YORK, March 06, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd (NASDAQ:PBM) ("Psyence Biomed" or the "Company") is pleased to announce that its wholly-owned subsidiary, Psyence Australia (Pty) Ltd ("Psyence Australia"), has received full approval from the Australian Health Research Ethics Committee (HREC) to initiate its planned Phase IIb study in Melbourne, Australia.
  • The study will examine the use of nature-derived psilocybin as a treatment for Adjustment Disorder due to a recent cancer diagnosis in the palliative care context.
  • Psyence Australia has partnered with a noted psychedelic Contract Research Organization (CRO), iNGENū Pty Ltd ("iNGENū"), to design and execute the clinical trial.
  • Psyence anticipates enrolling the first patient in Q2 2024 and expects the primary endpoint results to be available in 2025.

GN launches The New Norm – a stigma-busting image bank that challenges misperceptions about hearing loss and hearing aids

Retrieved on: 
Sunday, March 3, 2024

BALLERUP, Denmark, March 03, 2024 (GLOBE NEWSWIRE) -- Today GN launches The New Norm, a campaign aiming to tackle the visual misperception people have of modern hearing aids, which contributes to the high level of untreated hearing loss.

Key Points: 
  • On World Hearing Day, GN is launching a stigma-busting photography campaign showcasing real people with hearing loss – from world-class athletes to award-winning musicians – wearing their modern-day hearing aids.
  • BALLERUP, Denmark, March 03, 2024 (GLOBE NEWSWIRE) -- Today GN launches The New Norm, a campaign aiming to tackle the visual misperception people have of modern hearing aids, which contributes to the high level of untreated hearing loss.
  • In response, GN, a global leader in hearing technology, worked with photographer Gala Ricote (who has worn hearing aids for over 20 years) to photograph six inspiring hearing aid wearers.
  • The New Norm image bank provides access to free, high-quality images that represent the modern era of hearing aids and celebrates life with hearing loss.

Healis Therapeutics' asset CKDB-501A shares Phase III topline results for glabellar injections from CKD Bio in South Korea

Retrieved on: 
Tuesday, February 27, 2024

The study results demonstrated that CKDB-501A is non-inferior compared to the active-controlled BOTOX® by AbbVie (NYSE: ABBV) in improving moderate-to-severe glabellar lines.

Key Points: 
  • The study results demonstrated that CKDB-501A is non-inferior compared to the active-controlled BOTOX® by AbbVie (NYSE: ABBV) in improving moderate-to-severe glabellar lines.
  • A randomized, double-blind, active-controlled, multi-center Phase 3 trial to investigate the efficacy and safety of CKDB-501A in subjects with moderate-to-severe glabellar lines was completed in South Korea on November 20, 2023 (NCT05804656).
  • “This is clinically promising to see Healis’ lead protein, CKDB-501A, pass safety and efficacy in South Korea,” said Dr. Eric Finzi, Co-Founder of Healis Therapeutics.
  • Healis Therapeutics announced a strategic partnership with CKD Bio in 2024 to develop CKDB-501A for CNS indications.